Literature DB >> 6218584

Pharmacokinetics and clinical efficacy of moxalactam in biliary tract infections.

O Mueller, K Fabricius, E Krueger, U Rueckert.   

Abstract

Moxalactam exhibited excellent in vitro activity against all pathogens commonly associated with biliary tract infections. The drug retained bactericidal activity against all of these organisms, with the possible exception of Klebsiella pneumoniae, even in the presence of bile. Pharmacokinetic studies revealed high concentrations of moxalactam in the bile after intravenous administration. Twenty-seven of 28 patients with severe, complicated biliary tract infections responded favorably to the administration of moxalactam.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218584     DOI: 10.1093/clinids/4.supplement_3.s688

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  5 in total

1.  The pharmacokinetics of new cephalosporins: significance in clinical practice.

Authors:  H C Neu
Journal:  Bull N Y Acad Med       Date:  1984-05

2.  Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections.

Authors:  M G Bergeron; J Mendelson; G K Harding; L Mandell; I W Fong; A Rachlis; R Chan; S Biron; R Feld; N B Segal
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 4.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 5.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.